<p>Hims  Hers Health, Inc. (NYSE:HIMS - 獲取免費報告) 首席財務官 Oluyemi Okupe 於 5 月 18 日星期一出售了 7,950 股 Hims  Hers Health 股票。股票以平均價格 $23.64 出售，總價值為 $187,938.00。出售後，首席財務官直接持有該公司 262,954 股股票，價值 $6,216,232.56。此次交易使其持股減少了 2.93%。該出售在向證券交易委員會的備案中披露，相關信息可通過 SEC 網站訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。</p>
<p>獲取 <strong>Hims  Hers Health</strong> 的提醒：</p>
<ul>
<li>Hims  Hers 股票在第一季度業績不佳後暴跌：GLP-1 轉型是否足以推動復甦？</li>
</ul>
<p>Oluyemi Okupe 最近還進行了以下交易：</p>
<ul>
<li>4 月 20 日星期一，Oluyemi Okupe 出售了 19,645 股 Hims  Hers Health 股票。股票以平均價格 $29.96 出售，總價值為 $588,564.20。</li>
<li>4 月 16 日星期四，Oluyemi Okupe 出售了 36,922 股 Hims  Hers Health 股票。股票以平均價格 $25.90 出售，總價值為 $956,279.80。</li>
<li>4 月 17 日星期五，Oluyemi Okupe 出售了 18,005 股 Hims  Hers Health 股票。股票以平均價格 $27.83 出售，總交易額為 $501,079.15。</li>
<li>4 月 6 日星期一，Oluyemi Okupe 出售了 3,975 股 Hims  Hers Health 股票。股票以平均價格 $19.98 出售，總交易額為 $79,420.50。</li>
<li>3 月 20 日星期五，Oluyemi Okupe 出售了 9,217 股 Hims  Hers Health 股票。股票以平均價格 $23.77 出售，總交易額為 $219,088.09。</li>
</ul>
<h2>Hims  Hers Health 價格表現</h2>
<p>HIMS 股票在週二的午盤交易中上漲 $0.18，達到 $22.47。該公司交易了 27,295,336 股，相較於其平均交易量 28,940,582 股。該公司的 50 日移動平均價格為 $24.05，200 日移動平均價格為 $28.43。該公司的市值為 51.2 億美元，市盈率為 -249.61，PEG 比率為 39.32，貝塔值為 2.43。Hims  Hers Health, Inc. 的 12 個月低點為 $13.74，12 個月高點為 $70.43。該公司的債務與股本比率為 2.18，速動比率為 1.56，流動比率為 1.69。</p>
<ul>
<li>Hims  Hers 財報預覽：諾和諾德的轉變將 GLP-1 戰略置於焦點</li>
</ul>
<p>Hims  Hers Health (NYSE:HIMS - 獲取免費報告) 最近於 5 月 11 日星期一發布了季度財報。公司報告本季度每股收益為 ($0.40)，低於分析師一致預期的 $0.04，差距為 ($0.44)。本季度公司收入為 $608.10 百萬，而分析師預期為 $616.84 百萬。Hims  Hers Health 的淨利潤率為 -0.56%，股本回報率為 6.10%。與去年同期相比，Hims  Hers Health 的收入增長了 3.8%。在去年同期，該公司每股收益為 $0.20。平均而言，賣方分析師預計 Hims  Hers Health, Inc. 本年度每股收益將為 0.04。</p>
<h2>影響 Hims  Hers Health 的關鍵故事</h2>
<p>以下是本週影響 Hims  Hers Health 的關鍵新聞：</p>
<ul>
<li>積極情緒：更大規模的融資使 Hims  Hers 擁有更多資本，以追求國際擴張、收購計劃和技術投資，而無需使用過多的運營現金。Hims  Hers Health, Inc. 定價增發 3.5 億美元可轉換高級票據，以支持國際擴張並加速 AI 驅動的平台投資。</li>
<li>中性情緒：美國銀行將 Hims  Hers 的目標價從 $30 下調至 $28，並維持中性評級，儘管目標價仍高於近期股價，顯示出更謹慎的預期。Benzinga 報道美國銀行下調目標價。</li>
<li>消極情緒：投資者擔心可轉換票據可能會稀釋股東權益，這導致融資公告後股票下滑。為什麼 Hims  Hers 股票今天下跌。</li>
<li>消極情緒：公司的最新財報電話會議和最近的第一季度業績也使情緒保持疲軟，市場仍關注上個季度的業績不佳和低於預期的收入。Hims  Hers Health, Inc. 宣佈擬發行可轉換高級票據，以支持國際擴張並加速 AI 驅動的平台投資。</li>
</ul>
<h2>對 Hims  Hers Health 的對沖基金看法</h2>
<ul>
<li>FDA 最新提案對 Lilly、Novo 和 Hims 的影響</li>
</ul>
<p>幾家機構投資者和對沖基金最近增加或減少了在該公司的持股。瑞銀資產管理公司（UBS AM）在第一季度將其在 Hims  Hers Health 的持股增加了 23.1%。瑞銀資產管理公司現在擁有 418,699 股該公司的股票，價值 $12,373,000，此前在此期間又購買了 78,543 股。Geneos Wealth Management Inc. 在第一季度獲得了 Hims  Hers Health 的新頭寸，價值 $30,000。EverSource Wealth Advisors LLC 在第二季度將其在 Hims  Hers Health 的持股增加了 273.7%。EverSource Wealth Advisors LLC 現在擁有 938 股該公司的股票，價值 $47,000，此前在上個季度又購買了 687 股。Amundi 在第二季度將其在 Hims  Hers Health 的持股增加了 5.3%。Amundi 現在擁有 10,296 股該公司的股票，價值 $489,000，此前在此期間又購買了 522 股。最後，加利福尼亞公共僱員退休系統在第二季度將其在 Hims  Hers Health 的持股增加了 9.5%。加利福尼亞公共僱員退休系統現在擁有 338,620 股該公司的股票，價值 $16,880,000，此前在此期間又購買了 29,471 股。63.52% 的股票目前由對沖基金和其他機構投資者持有。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾位研究分析師最近對該公司發表了看法。Evercore 在 2 月 24 日的研究報告中對 Hims &amp; Hers Health 設定了 24.00 美元的目標價。Weiss Ratings 在 5 月 12 日的研究報告中將 Hims &amp; Hers Health 的評級從 “持有 (c)” 下調至 “賣出 (d)”。Wall Street Zen 在 5 月 9 日的報告中將 Hims &amp; Hers Health 的評級從 “持有” 下調至 “賣出”。Barclays 在 3 月 11 日的研究報告中將 Hims &amp; Hers Health 的目標價從 25.00 美元上調至 29.00 美元，並給予該股票 “增持” 評級。最後，Truist Financial 在 2 月 24 日的研究報告中重申了 “持有” 評級，並將 Hims &amp; Hers Health 的目標價下調至 18.00 美元（低於 37.00 美元）。四位分析師對該股票給予了買入評級，十一位分析師給予了持有評級，兩位分析師給予了賣出評級。根據 MarketBeat 的數據，該公司的平均評級為 “持有”，平均目標價為 29.37 美元。</p>
<p><strong>查看我們關於 Hims &amp; Hers Health 的最新研究報告</strong></p>
<h2>關於 Hims &amp; Hers Health</h2>
<p>(獲取免費報告)</p>
<p>Hims &amp; Hers Health, Inc 是一個遠程醫療平台，提供直接面向消費者的個人護理產品和虛擬醫療服務。該公司以 Hims &amp; Hers 品牌運營，提供一個綜合的數字體驗，將用户與持牌醫療提供者連接，使其能夠進行在線諮詢和開處方，涵蓋多種健康問題。其遠程醫療基礎設施支持處方藥和非處方產品，並提供送貨上門服務。</p>
<p>該公司的產品組合涵蓋男性和女性健康的關鍵領域，包括脱髮治療、性健康療法、護膚方案和心理健康支持。</p>
<h2>進一步閲讀</h2>
<ul>
<li>五隻我們認為比 Hims &amp; Hers Health 更好的股票</li>
<li>HIVE 利用電力進行 AI 轉型</li>
<li>深入探討 NVIDIA 最新的投資組合動態</li>
<li>Brady Corp 進行大規模 AI 驅動的突破</li>
<li>為什麼 Home Depot 的拋售可能成為一個巨大機會</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Hims &amp; Hers Health 嗎？</h2>
<p>在考慮 Hims &amp; Hers Health 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Hims &amp; Hers Health 並不在名單上。</p>
<p>雖然 Hims &amp; Hers Health 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

HIMS

醫療業 ETF - Vanguard

標普醫療保健服務 ETF - SPDR

美國醫療保健供應商 ETF - iShares

2 倍做多 HIMS ETF - Defiance

HIMY

醫療業 ETF - SPDR

標普全球醫療股指數 ETF - iShares

<p>Hims & Hers Health 首席財務官 Oluyemi Okupe 以每股 23.64 美元的價格出售了 7,950 股，總計 187,938 美元，減少了 2.93% 的持股。出售後，他持有 262,954 股，價值約 622 萬美元。此次交易是預先安排的交易計劃的一部分，並已向美國證券交易委員會（SEC）披露。該公司的股票經歷了波動，最近的收益未達到預期，市值為 51.2 億美元</p>

<p>Hims &amp; Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 7,950 shares of Hims &amp; Hers Health stock in a transaction on Monday, May 18th. The shares were sold at an average price of $23.64, for a total value of $187,938.00. Following the sale, the chief financial officer directly owned 262,954 shares in the company, valued at $6,216,232.56. The trade was a 2.93% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.</p>
<div class="lb-trans"><p>Hims  Hers Health, Inc. (NYSE:HIMS - 獲取免費報告) 首席財務官 Oluyemi Okupe 於 5 月 18 日星期一出售了 7,950 股 Hims  Hers Health 股票。股票以平均價格 $23.64 出售，總價值為 $187,938.00。出售後，首席財務官直接持有該公司 262,954 股股票，價值 $6,216,232.56。此次交易使其持股減少了 2.93%。該出售在向證券交易委員會的備案中披露，相關信息可通過 SEC 網站訪問。該交易是在預先安排的 10b5-1 交易計劃下執行的。</p>
</div><p>Get <strong>Hims &amp; Hers Health</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Hims  Hers Health</strong> 的提醒：</p>
</div><ul>
<li>Hims &amp; Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims  Hers 股票在第一季度業績不佳後暴跌：GLP-1 轉型是否足以推動復甦？</li>
</ul>
</div><p>Oluyemi Okupe also recently made the following trade(s):</p>
<div class="lb-trans"><p>Oluyemi Okupe 最近還進行了以下交易：</p>
</div><ul>
<li>On Monday, April 20th, Oluyemi Okupe sold 19,645 shares of Hims &amp; Hers Health stock. The stock was sold at an average price of $29.96, for a total value of $588,564.20.</li>
<li>On Thursday, April 16th, Oluyemi Okupe sold 36,922 shares of Hims &amp; Hers Health stock. The shares were sold at an average price of $25.90, for a total value of $956,279.80.</li>
<li>On Friday, April 17th, Oluyemi Okupe sold 18,005 shares of Hims &amp; Hers Health stock. The stock was sold at an average price of $27.83, for a total transaction of $501,079.15.</li>
<li>On Monday, April 6th, Oluyemi Okupe sold 3,975 shares of Hims &amp; Hers Health stock. The shares were sold at an average price of $19.98, for a total transaction of $79,420.50.</li>
<li>On Friday, March 20th, Oluyemi Okupe sold 9,217 shares of Hims &amp; Hers Health stock. The shares were sold at an average price of $23.77, for a total transaction of $219,088.09.</li>
</ul>
<div class="lb-trans"><ul>
<li>4 月 20 日星期一，Oluyemi Okupe 出售了 19,645 股 Hims  Hers Health 股票。股票以平均價格 $29.96 出售，總價值為 $588,564.20。</li>
<li>4 月 16 日星期四，Oluyemi Okupe 出售了 36,922 股 Hims  Hers Health 股票。股票以平均價格 $25.90 出售，總價值為 $956,279.80。</li>
<li>4 月 17 日星期五，Oluyemi Okupe 出售了 18,005 股 Hims  Hers Health 股票。股票以平均價格 $27.83 出售，總交易額為 $501,079.15。</li>
<li>4 月 6 日星期一，Oluyemi Okupe 出售了 3,975 股 Hims  Hers Health 股票。股票以平均價格 $19.98 出售，總交易額為 $79,420.50。</li>
<li>3 月 20 日星期五，Oluyemi Okupe 出售了 9,217 股 Hims  Hers Health 股票。股票以平均價格 $23.77 出售，總交易額為 $219,088.09。</li>
</ul>
</div><h2>Hims &amp; Hers Health Price Performance</h2>
<div class="lb-trans"><h2>Hims  Hers Health 價格表現</h2>
</div><p>Shares of HIMS stock traded up $0.18 during midday trading on Tuesday, reaching $22.47. 27,295,336 shares of the company were exchanged, compared to its average volume of 28,940,582. The company's 50 day moving average price is $24.05 and its two-hundred day moving average price is $28.43. The company has a market cap of $5.12 billion, a P/E ratio of -249.61, a PEG ratio of 39.32 and a beta of 2.43. Hims &amp; Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $70.43. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69.</p>
<div class="lb-trans"><p>HIMS 股票在週二的午盤交易中上漲 $0.18，達到 $22.47。該公司交易了 27,295,336 股，相較於其平均交易量 28,940,582 股。該公司的 50 日移動平均價格為 $24.05，200 日移動平均價格為 $28.43。該公司的市值為 51.2 億美元，市盈率為 -249.61，PEG 比率為 39.32，貝塔值為 2.43。Hims  Hers Health, Inc. 的 12 個月低點為 $13.74，12 個月高點為 $70.43。該公司的債務與股本比率為 2.18，速動比率為 1.56，流動比率為 1.69。</p>
</div><ul>
<li>Hims &amp; Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus</li>
</ul>
<div class="lb-trans"><ul>
<li>Hims  Hers 財報預覽：諾和諾德的轉變將 GLP-1 戰略置於焦點</li>
</ul>
</div><p>Hims &amp; Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of $0.04 by ($0.44). The company had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. Hims &amp; Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. Hims &amp; Hers Health's revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.20 EPS. On average, sell-side analysts expect that Hims &amp; Hers Health, Inc. will post 0.04 earnings per share for the current year.</p>
<div class="lb-trans"><p>Hims  Hers Health (NYSE:HIMS - 獲取免費報告) 最近於 5 月 11 日星期一發布了季度財報。公司報告本季度每股收益為 ($0.40)，低於分析師一致預期的 $0.04，差距為 ($0.44)。本季度公司收入為 $608.10 百萬，而分析師預期為 $616.84 百萬。Hims  Hers Health 的淨利潤率為 -0.56%，股本回報率為 6.10%。與去年同期相比，Hims  Hers Health 的收入增長了 3.8%。在去年同期，該公司每股收益為 $0.20。平均而言，賣方分析師預計 Hims  Hers Health, Inc. 本年度每股收益將為 0.04。</p>
</div><h2>Key Stories Impacting Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>影響 Hims  Hers Health 的關鍵故事</h2>
</div><p>Here are the key news stories impacting Hims &amp; Hers Health this week:</p>
<div class="lb-trans"><p>以下是本週影響 Hims  Hers Health 的關鍵新聞：</p>
</div><ul>
<li>Positive Sentiment: The larger financing gives Hims &amp; Hers more capital to pursue international expansion, acquisition plans, and technology investment without using as much operating cash. Hims &amp; Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment</li>
<li>Neutral Sentiment: Bank of America lowered its price target on Hims &amp; Hers to $28 from $30 and kept a neutral rating, signaling more cautious expectations even though the target still sits above the recent share price. Benzinga report on Bank of America price target cut</li>
<li>Negative Sentiment: Investors are worried the convertible notes could dilute shareholders later, which has contributed to the stock sliding after the financing announcement. Why Hims &amp; Hers Stock Is Falling Today</li>
<li>Negative Sentiment: The company’s latest earnings call and recent Q1 results have also kept sentiment weak, with the market still focused on the prior quarter’s earnings miss and softer-than-expected revenue. Hims &amp; Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment</li>
</ul>
<div class="lb-trans"><ul>
<li>積極情緒：更大規模的融資使 Hims  Hers 擁有更多資本，以追求國際擴張、收購計劃和技術投資，而無需使用過多的運營現金。Hims  Hers Health, Inc. 定價增發 3.5 億美元可轉換高級票據，以支持國際擴張並加速 AI 驅動的平台投資。</li>
<li>中性情緒：美國銀行將 Hims  Hers 的目標價從 $30 下調至 $28，並維持中性評級，儘管目標價仍高於近期股價，顯示出更謹慎的預期。Benzinga 報道美國銀行下調目標價。</li>
<li>消極情緒：投資者擔心可轉換票據可能會稀釋股東權益，這導致融資公告後股票下滑。為什麼 Hims  Hers 股票今天下跌。</li>
<li>消極情緒：公司的最新財報電話會議和最近的第一季度業績也使情緒保持疲軟，市場仍關注上個季度的業績不佳和低於預期的收入。Hims  Hers Health, Inc. 宣佈擬發行可轉換高級票據，以支持國際擴張並加速 AI 驅動的平台投資。</li>
</ul>
</div><h2>Hedge Funds Weigh In On Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>對 Hims  Hers Health 的對沖基金看法</h2>
</div><ul>
<li>What the FDA's Latest Proposal Means for Lilly, Novo, and Hims</li>
</ul>
<div class="lb-trans"><ul>
<li>FDA 最新提案對 Lilly、Novo 和 Hims 的影響</li>
</ul>
</div><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Hims &amp; Hers Health by 23.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company's stock worth $12,373,000 after buying an additional 78,543 shares during the period. Geneos Wealth Management Inc. acquired a new position in Hims &amp; Hers Health during the first quarter valued at $30,000. EverSource Wealth Advisors LLC lifted its stake in Hims &amp; Hers Health by 273.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company's stock worth $47,000 after acquiring an additional 687 shares in the last quarter. Amundi boosted its position in Hims &amp; Hers Health by 5.3% during the 2nd quarter. Amundi now owns 10,296 shares of the company's stock worth $489,000 after acquiring an additional 522 shares during the period. Finally, California Public Employees Retirement System boosted its position in Hims &amp; Hers Health by 9.5% during the 2nd quarter. California Public Employees Retirement System now owns 338,620 shares of the company's stock worth $16,880,000 after acquiring an additional 29,471 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近增加或減少了在該公司的持股。瑞銀資產管理公司（UBS AM）在第一季度將其在 Hims  Hers Health 的持股增加了 23.1%。瑞銀資產管理公司現在擁有 418,699 股該公司的股票，價值 $12,373,000，此前在此期間又購買了 78,543 股。Geneos Wealth Management Inc. 在第一季度獲得了 Hims  Hers Health 的新頭寸，價值 $30,000。EverSource Wealth Advisors LLC 在第二季度將其在 Hims  Hers Health 的持股增加了 273.7%。EverSource Wealth Advisors LLC 現在擁有 938 股該公司的股票，價值 $47,000，此前在上個季度又購買了 687 股。Amundi 在第二季度將其在 Hims  Hers Health 的持股增加了 5.3%。Amundi 現在擁有 10,296 股該公司的股票，價值 $489,000，此前在此期間又購買了 522 股。最後，加利福尼亞公共僱員退休系統在第二季度將其在 Hims  Hers Health 的持股增加了 9.5%。加利福尼亞公共僱員退休系統現在擁有 338,620 股該公司的股票，價值 $16,880,000，此前在此期間又購買了 29,471 股。63.52% 的股票目前由對沖基金和其他機構投資者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several research analysts recently weighed in on the company. Evercore set a $24.00 target price on Hims &amp; Hers Health in a research note on Tuesday, February 24th. Weiss Ratings lowered Hims &amp; Hers Health from a &#34;hold (c)&#34; rating to a &#34;sell (d)&#34; rating in a research note on Tuesday, May 12th. Wall Street Zen cut Hims &amp; Hers Health from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, May 9th. Barclays boosted their target price on Hims &amp; Hers Health from $25.00 to $29.00 and gave the stock an &#34;overweight&#34; rating in a research report on Wednesday, March 11th. Finally, Truist Financial reiterated a &#34;hold&#34; rating and issued a $18.00 price target (down from $37.00) on shares of Hims &amp; Hers Health in a research report on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of &#34;Hold&#34; and an average price target of $29.37.</p>
<div class="lb-trans"><p>幾位研究分析師最近對該公司發表了看法。Evercore 在 2 月 24 日的研究報告中對 Hims &amp; Hers Health 設定了 24.00 美元的目標價。Weiss Ratings 在 5 月 12 日的研究報告中將 Hims &amp; Hers Health 的評級從 “持有 (c)” 下調至 “賣出 (d)”。Wall Street Zen 在 5 月 9 日的報告中將 Hims &amp; Hers Health 的評級從 “持有” 下調至 “賣出”。Barclays 在 3 月 11 日的研究報告中將 Hims &amp; Hers Health 的目標價從 25.00 美元上調至 29.00 美元，並給予該股票 “增持” 評級。最後，Truist Financial 在 2 月 24 日的研究報告中重申了 “持有” 評級，並將 Hims &amp; Hers Health 的目標價下調至 18.00 美元（低於 37.00 美元）。四位分析師對該股票給予了買入評級，十一位分析師給予了持有評級，兩位分析師給予了賣出評級。根據 MarketBeat 的數據，該公司的平均評級為 “持有”，平均目標價為 29.37 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Hims &amp; Hers Health</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Hims &amp; Hers Health 的最新研究報告</strong></p>
</div><h2>About Hims &amp; Hers Health</h2>
<div class="lb-trans"><h2>關於 Hims &amp; Hers Health</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Hims &amp; Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims &amp; Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.</p>
<div class="lb-trans"><p>Hims &amp; Hers Health, Inc 是一個遠程醫療平台，提供直接面向消費者的個人護理產品和虛擬醫療服務。該公司以 Hims &amp; Hers 品牌運營，提供一個綜合的數字體驗，將用户與持牌醫療提供者連接，使其能夠進行在線諮詢和開處方，涵蓋多種健康問題。其遠程醫療基礎設施支持處方藥和非處方產品，並提供送貨上門服務。</p>
</div><p>The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.</p>
<div class="lb-trans"><p>該公司的產品組合涵蓋男性和女性健康的關鍵領域，包括脱髮治療、性健康療法、護膚方案和心理健康支持。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Hims &amp; Hers Health</li>
<li>HIVE Weaponizes Power for an AI Pivot</li>
<li>A Deep Dive Into NVIDIA’s Latest Portfolio Moves</li>
<li>Brady Corp Wires Up a Massive AI-Powered Breakout</li>
<li>Why Home Depot’s Sell-Off Could Become a Huge Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比 Hims &amp; Hers Health 更好的股票</li>
<li>HIVE 利用電力進行 AI 轉型</li>
<li>深入探討 NVIDIA 最新的投資組合動態</li>
<li>Brady Corp 進行大規模 AI 驅動的突破</li>
<li>為什麼 Home Depot 的拋售可能成為一個巨大機會</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhJTVM" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NYSE&amp;Symbol=HIMS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Hims &amp; Hers Health Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Hims &amp; Hers Health 嗎？</h2>
</div><p>Before you consider Hims &amp; Hers Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Hims &amp; Hers Health 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hims &amp; Hers Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Hims &amp; Hers Health 並不在名單上。</p>
</div><p>While Hims &amp; Hers Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Hims &amp; Hers Health 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Insider Selling: Hims & Hers Health (NYSE:HIMS) CFO Sells 7,950 Shares of Stock

Market Beat

Hims & Hers Health

Defiance Leveraged Long +Income HIMS ETF

禮來

諾和諾德公司

美國銀行

瑞銀集團

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

內部人士出售：Hims & Hers Health（NYSE:HIMS）的首席財務官出售了 7,950 股股票